These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35714312)

  • 21. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
    Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
    Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enasidenib for the treatment of acute myeloid leukemia.
    Dugan J; Pollyea D
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
    Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
    Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Döhner H; Dolnik A; Tang L; Seymour JF; Minden MD; Stone RM; Del Castillo TB; Al-Ali HK; Santini V; Vyas P; Beach CL; MacBeth KJ; Skikne BS; Songer S; Tu N; Bullinger L; Dombret H
    Leukemia; 2018 Dec; 32(12):2546-2557. PubMed ID: 30275526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive First Trial of Enasidenib for AML.
    Cancer Discov; 2017 Aug; 7(8):OF1. PubMed ID: 28659444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
    Galkin M; Jonas BA
    Core Evid; 2019; 14():3-17. PubMed ID: 31118877
    [No Abstract]   [Full Text] [Related]  

  • 31. Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
    Song A; Altabbakh O; Sallman DA; Padron E; Talati C; Hussaini MO
    Eur J Haematol; 2021 Dec; 107(6):609-616. PubMed ID: 34407254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
    J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating Full Bayesian Inference and Student's t-Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug-Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients.
    Cheng Y; Du S; Hu H; Wang X; Carayannopoulos L; Li Y
    J Clin Pharmacol; 2024 Jul; 64(7):866-877. PubMed ID: 38478303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
    Libura M; Bialopiotrowicz E; Giebel S; Wierzbowska A; Roboz GJ; Piatkowska-Jakubas B; Pawelczyk M; Gorniak P; Borg K; Wojtas M; Florek I; Matiakowska K; Jazwiec B; Solarska I; Noyszewska-Kania M; Piechna K; Zawada M; Czekalska S; Salamanczuk Z; Karabin K; Wasilewska K; Paluszewska M; Urbanowska E; Gajkowska-Kulik J; Semenczuk G; Rybka J; Wrobel T; Ejduk A; Kata D; Grosicki S; Robak T; Pluta A; Kominek A; Piwocka K; Pyziak K; Sroka-Porada A; Wrobel A; Przybylowicz A; Wojtaszewska M; Lewandowski K; Gil L; Piekarska A; Knopinska W; Bolkun L; Warzocha K; Kuliczkowski K; Sacha T; Basak G; Jedrzejczak WW; Holowiecki J; Juszczynski P; Haus O
    Sci Rep; 2021 May; 11(1):10017. PubMed ID: 33976256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enasidenib: First Global Approval.
    Kim ES
    Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
    Fathi AT; Kim HT; Soiffer RJ; Levis MJ; Li S; Kim AS; Mims AS; DeFilipp Z; El-Jawahri A; McAfee SL; Brunner AM; Narayan R; Knight LW; Kelley D; Bottoms AS; Perry LH; Wahl JL; Brock J; Breton E; Ho VT; Chen YB
    Blood Adv; 2022 Nov; 6(22):5857-5865. PubMed ID: 36150050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
    Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.
    Myers RA; Wirth S; Williams S; Kiel PJ
    J Adv Pract Oncol; 2018; 9(4):435-440. PubMed ID: 30719396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.